Sole US Patent Protecting Apriso Mesalamine Capsules Is Obvious
In a ruling favouring Mylan, GeneriCo and Flat Line Capital, The US Court of Appeals has confirmed an inter partes review finding that key claims of the sole patent listed against Bausch Health’s Apriso mesalamine brand are unpatentable as obvious.
You may also be interested in...
Bausch Health has settled its patent litigation with Teva over the Canadian firm’s ulcerative colitis medicine Apriso (mesalamine) 375mg extended-release capsules. The deal gives Teva the right to market a generic version of Apriso in the US in 2021, nine years before the patent on the drug expires.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.